POLISCOPE
Back to feed
NewsABC7 News San Francisco (KGO-TV)November 19, 2026San Francisco County

Novo Nordisk clinical trial shows Wegovy reduces BMI in children ages 6 to 11

Photo: ABC7 News San Francisco (KGO-TV)

New clinical trial results show that the weight-loss drug Wegovy reduced Body Mass Index by 10% or more in children ages 6 through 11, prompting the manufacturer to plan an FDA application to lower the approved age. While some doctors view the findings as a promising way to treat childhood obesity and related complications, others raise concerns about common gastrointestinal side effects and potential impacts on linear growth.

Read the full story at ABC7 News San Francisco (KGO-TV)

Why It Matters

The findings could lead to the expanded use of medications for children as young as 6, altering treatment options for the approximately one in five U.S. children and adolescents affected by obesity.

Key Facts

  • Novo Nordisk shared phase 3 clinical trial results showing Wegovy reduced Body Mass Index by 10% or more among most children with obesity ages 6 through 11.
  • After 68 weeks of taking semaglutide, almost 40% of children in the trial no longer had obesity, compared to nearly all patients taking the placebo.
  • Novo Nordisk plans to file with the Food and Drug Administration to lower the approved age for Wegovy from 12 years old.
  • The World Health Organization recommends against children under 10 receiving pharmacological weight-loss treatments, advising a focus on diet and exercise instead.
  • The Centers for Disease Control and Prevention estimates that approximately one in five U.S. children and adolescents have obesity.
  • Gastrointestinal side effects were more common in the semaglutide group: vomiting occurred in 70% of participants, diarrhea in 62%, and nausea in 58%.
  • Children in the semaglutide group grew about 1.3 inches less in linear growth compared to those in the placebo group during the trial.

Who's Mentioned